ERAP1,2 in Recalcitrant Warts

Completed

• Conditions: Warts

• Registration Number: NCT06833164
• Lead Sponsor: Benha University

Brief Summary

The exact mechanisms underlying the contribution of cellular immunity in the eradication of human papillomavirus (HPV) infections remain obscure. Individuals who have treatment-resistant warts frequently have immune deficiencies. Amino-peptidases (ERAP1, ERAP2) of endoplasmic reticulum are essential for production of antigenic epitopes that attach to the Major Histocompatibility Complex (MHC) class I and activate T-lymphocytes or natural killer (NK) cells. Aim: To assess ERAP1 and ERAP2 serum concentrations in patients with resistant warts.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-01
• Primary Completion: 2024-03-20
• Study Completion: 2024-03-20
• Status Verified: 2025-02
• Study First Submitted: 2025-02-13
• Study First Submitted QC: 2025-02-17
• Last Update Submitted: 2025-02-17
• Study First Posted: 2025-02-18
• Last Update Posted: 2025-02-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patients who had a history of incomplete clearance or recurrence following two or more electrocautery sessions and four or more cryocautery treatments and intralesional bleomycin.

Exclusion Criteria

• Patients with genital warts
• Patients on systemic steroids or other immunosuppressive treatments
• Immunocompromised individuals
• Patients suffering from chronic systemic diseases
• Pregnant women

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SERUM LEVELS OF endoplasmic reticulum aminopeptidase 1 and 2	ONE YEAR	using specific Commercial human ELISA kits

Trial Locations

Locations (1)

faculty of medicine Benha University; 🇪🇬 Benha, Qalubia, Egypt